Humacyte
HUMA
83 hedge funds and large institutions have $48.7M invested in Humacyte in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 12 reducing their positions, and 8 closing their positions.
217% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 12
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
15% more capital invested
Capital invested by funds: $42.2M → $48.7M (+$6.45M)
11% more funds holding
Funds holding: 75 → 83 (+8)
1.81% more ownership
Funds ownership: 14.24% → 16.06% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
88% less call options, than puts
Call options by funds: $44K | Put options by funds: $356K
Top Buyers
| 1 |
Millennium Management
New York
|
+$4.06M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$792K |
| 3 |
LPC
Lion Point Capital
New York
|
+$778K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$686K |
| 5 |
BlackRock
New York
|
+$648K |
Top Sellers
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$1.28M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
-$1.14M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.07M |
| 4 |
IW
Imprint Wealth
Mount Pleasant,
South Carolina
|
-$161K |
| 5 |
Barclays
London,
United Kingdom
|
-$156K |
HUMA Hedge Fund Activity: Q3 2023 in Review
83 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2023, worth a combined $48.7M — up 15% from $42.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HUMA positions and 8 closed out — a net gain of 8 holders — while 38 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $4.06M. The largest seller was Davidson Kempner Capital Management, exiting entirely with an estimated $1.28M sold.
- 83 institutional investors held Humacyte (HUMA) as of Q3 2023, up from 75 in Q2 2023.
- Funds reported $48.7M of Humacyte stock for Q3 2023, up 15% quarter-over-quarter.
- 16 funds opened new Humacyte positions in Q3 2023 and 8 closed out, a net change of +8 holders.
- The largest Humacyte buyer in Q3 2023 was Millennium Management, an estimated $4.06M added.
- The largest Humacyte seller in Q3 2023 was Davidson Kempner Capital Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2023.